Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial

Published:2023-01 Issue:1 Volume:83 Page:82-89
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Vignani Francesca,Tambaro Rosa,De Giorgi Ugo,Giannatempo Patrizia,Bimbatti Davide,Carella Claudia,Stellato Marco,Atzori Francesco,Aieta Michele,Masini Cristina,Hamzaj Alketa,Ermacora Paola,Veccia Antonello,Scandurra Giuseppa,Gamba Teresa,Ignazzi Gianluca,Pignata Sandro,Di Napoli Marilena,Lolli Cristian,Procopio Giuseppe,Pierantoni Francesco,Zonno Antonia,Santini Daniele,Di Maio Massimo

Funder

GlaxoSmithKline

PharmaMar

Novartis

Ipsen

Roche

Sanofi

Bayer

Clovis Oncology

Astellas Pharma US

AstraZeneca

GlaxoSmithKline USA Rockville

Pfizer

Meso Scale Diagnostics

Publisher

Elsevier BV

Subject

Urology

Reference23 articles.

1. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Powles;Ann Oncol,2022

2. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma;Cathomas;Eur Urol,2022

3. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000

4. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005

5. DNA repair pathway alterations in bladder cancer;Mouw;Cancers (Basel).,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Similar genetic profile in early and late stage urothelial tract cancer;Journal of Cancer Research and Clinical Oncology;2024-07-08

2. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution;International Journal of Clinical Oncology;2024-06-08

3. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis;Expert Review of Anticancer Therapy;2024-05-23

4. Inhibition of cyclin D1 by new biguanide 4C increases the sensitivity of proficient homologous recombination repair bladder cancer cells to Olaparib via causing G0 / G1 arrest;2024-04-02

5. PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety;Bladder Cancer;2023-12-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3